Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

36,960 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study.
Ma Y, Chen Q, Zhang Y, Xue J, Liu Q, Zhao Y, Yang Y, Huang Y, Fang W, Hou Z, Li S, Wang J, Zhang L, Zhao H. Ma Y, et al. Among authors: zhao h, zhao y. Cancer Chemother Pharmacol. 2023 Nov;92(5):411-418. doi: 10.1007/s00280-023-04563-2. Epub 2023 Jul 31. Cancer Chemother Pharmacol. 2023. PMID: 37518060
The first-in-class bispecific antibody IBI318 (LY3434172) targeting PD-1 and PD-L1 in patients with advanced tumors: a phase Ia/Ib study.
Ruan DY, Wei XL, Liu FR, Hu XC, Zhang J, Ji DM, Huang DZ, Zhao YQ, Pan HM, Liao WJ, Yang KY, Xu N, Lu XX, Chen YL, Zhang W, Zhou H, Zhao HY, Xu RH. Ruan DY, et al. Among authors: zhao yq, zhao hy. J Hematol Oncol. 2024 Nov 29;17(1):118. doi: 10.1186/s13045-024-01644-4. J Hematol Oncol. 2024. PMID: 39614368 Free PMC article. Clinical Trial.
Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial.
Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, He ZY, Chen NY, Hu WH, Wu HJ, Shi M, Zhou GQ, Mao YP, Guo R, Sun R, Huang J, Liang SQ, Wu WL, Su Z, Li L, Ai P, He YX, Zang J, Chen L, Lin L, Huang SH, Xu C, Lv JW, Li YQ, Hong SB, Jie YS, Li H, Huang SW, Liang YL, Wang YQ, Peng YL, Zhu JH, Zang SB, Liu SR, Lin QG, Li HJ, Tian L, Liu LZ, Zhao HY, Lin AH, Li JB, Liu N, Tang LL, Chen YP, Sun Y, Ma J. Liu X, et al. Among authors: zhao hy. Lancet. 2024 Jun 22;403(10445):2720-2731. doi: 10.1016/S0140-6736(24)00594-4. Epub 2024 May 30. Lancet. 2024. PMID: 38824941 Clinical Trial.
[Predictive model for ejection fraction improvement at one year in patients with acute ST-segment elevation myocardial infarction complicated with heart failure with reduced ejection fraction].
Tao ZY, Zhao H, Wang Z, Chai YZ, Guo XN, Wu QZ, Wang YN, Wu C, Ni LY, Li XX, Zhou YP, Li CY, Li XL, Sun XW, Jiang M, Pu J. Tao ZY, et al. Among authors: zhao h. Zhonghua Yi Xue Za Zhi. 2025 Jan 28;105(4):297-305. doi: 10.3760/cma.j.cn112137-20241023-02390. Zhonghua Yi Xue Za Zhi. 2025. PMID: 39865014 Chinese.
36,960 results
You have reached the last available page of results. Please see the User Guide for more information.